You can buy or sell EDIT and other stocks, options, ETFs, and crypto commission-free!
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9). Read More The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Yahoo FinanceMay 19
Edited Transcript of EDIT earnings conference call or presentation 7-May-19 9:00pm GMT
Q1 2019 Editas Medicine Inc Earnings Call Cambridge May 20, 2019 (Thomson StreetEvents) -- Edited Transcript of Editas Medicine Inc earnings conference call or presentation Tuesday, May 7, 2019 at 9:00:00pm GMT TEXT version of Transcript Scroll to continue with content Ad ================================================================================ Corporate Participants ================================================================================ * Charles Albright Editas Medicine, Inc. - Chi...
Seeking AlphaMay 14
May Outlook On Editas Medicine
Without more clinical news, analysis shows an opportunity for a short-term bump upward until it hits resistance points again. Stock prices have traded without much more news inside resistance near the $27 and support just under $20. Editas has seen bounce back from concerns in 2018 of its portfolio, and gained on news of its EDIT-101 clinicals. Editas (EDIT) has resumed the uptrend after a bearish pullback to the 78.6% Fibonacci retracement price of $19.82. Price is now at the 61.8% Fibonacci retracement...
The Motley FoolMay 8
Editas Gears Up for a Busy 2019
Editas Medicine (NASDAQ:EDIT) released first-quarter 2019 results on Tuesday after the market closed. The genome-editing leader highlighted the continued march of its primary EDIT-101 drug candidate, for treating Leber congenital amaurosis type 10 (LCA10), toward a historic dose-escalation study later this year; progress on its earlier stage medicine-development initiatives; and a promising new partnership to further extend its reach. With shares down up around 2% on Wednesday in response, let's have a clo...
Expected Aug 6, After Hours